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Condensation 
With the advancement in modern diagnostics many cases of breast cancer are diagnosed in  
women who delay childbearing. The risk of infertility is a potential hardship to be faced by 
the patients. There are several options for women desiring preservation of fertility, including 
in-vitro fertilization, in vitro maturation, and oocyte/embryo/ovarian tissue cryopreservation. 
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Abstract  
In many modern countries of the developed world, there is an increasing trend toward 
delay in childbearing from 30 to 40 years of age for different reasons. Improvement of 
diagnostic and therapeutic methods is unfortunately concordant with the increasing incidence 
of breast cancer in women who have not yet completed their family. Current choice for 
premenopausal women is an adjuvant therapy, which includes cytotoxic chemotherapy, 
ovarian ablation (by surgery, irradiation, or chemical ovarian supression), anti-oestrogen 
therapy, or any combination of these. Although the use of adjuvant therapies with cytotoxic 
drugs can significantly reduce the mortality in the majority of young women with breast 
cancer, it raises issues of the long-term toxicity, such as induction of an early menopause and 
fertility impairment. The risk of infertility is a potential hardship to be faced by the patients 
following treatment of breast cancer. The offspring of patients who became pregnant after 
completion of chemotherapy have shown no adverse effects and congenital anomalies from 
the treatment, but sometimes high abortion (29%) and premature deliveries with low birth 
weight (40%) rates have been demonstrated. Therefore, the issue of recent cytotoxic treatment 
remains controversial and further researches are required to define a “safety period” between 
cessation of treatment and pregnancy. Preservation of fertility in breast cancer survivors at 
reproductive age has become an important issue regarding the quality of life. Currently, there 
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are several potential options for women facing premature ovarian failure and desiring 
preservation of fertility, including all available assisted technologies, such as in-vitro 
fertilization and embryo transfer, in vitro maturation, oocyte and embryo cryopreservation, 
and cryopreservation of ovarian tissue. Because increased estrogen levels are thought to be 
potentially risky in breast cancer patients, recently developed ovarian stimulation protocols 
with aromatase inhibitor letrozole and tamoxifen appear to provide a safe stimulation with 
endogenous estrogen. Since recently, embryo cryopreservation seems to be the most 
established fertility preservation strategy, providing 25 to 35% chance of pregnancy. In 
addition, oocyte freezing can be considered as an alternative in patients that are single and in 
those who do not wish a sperm donor. Although ovarian tissue harvesting appears to be safe,   
the experience regarding ovarian transplantation is still limited due to low utilization, so the 
true value of this procedure remains to be determined. Nevertheless, in clinical situations in 
which chemotherapy needs to be started in young patients facing premature ovarian failure, 
ovarian tissue preservation seems to be a promissing option of restoring fertility, especially in 
conjuction with other options like immature oocyte retrieval, in-vitro maturation of oocytes, 
oocyte vitrification, or embryo cryopreservation. It seems that in-vitro maturation is a useful 
strategy because it improves oocyte or cryopreservation outcome in breast cancer patients  
undergoing ovarian stimulation for fertility preservation. 
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1. Introduction 
The appearance of breast cancer increases progressively with the older age with a 
maximum in postmenopausal women. However, an increase in the incidence of breast cancer 
in women aged <40 years has been reported in recent years in many Western countries. Mean 
annual changes in the incidence rate for the calendar period 1995-2006 from all European 
cancer registries were 1.032 and 1.014 in women aged 20-29 and 30-39 years old at diagnosis, 
respectively [1]. In the USA, the incidence of breast cancer with distant involvement at 
diagnosis increased in 25- to 39-year-old women from 1.53 per 100,000 in 1976 to 2.90 per 
100,000 in 2009. This is an absolute difference of 1.37 per 100,000, representing an average 
compounded increase of 2.07% per year over the 34-year interval [2].  
In many countries of developed world, an increasing trend toward delay in 
childbearing from 30 to 40 years of age for different reasons (educational, professional,  
personal, socioeconomic, and fertility problems), in addition to improved diagnostic and 
therapeutic  methods, is concordant  with the increasing incidence of breast cancer in women 
who have not yet completed their family. An increased breast cancer risk with advancing 
maternal age at first childbirth  is supported by 3,7 relative risk in women with an estimated 
first median age of 41 years, compared with those with an estimated first birth age of 23 years 
[3].  
Because the incidence of premenopausal women with breast carcinoma delaying 
pregnancy is increasing, they may have concerns regarding preservation of ovarian function 
due to advanced reproductive age and whether breast cancer treatment would interfere with 
the outcome of later fertility. The risk of infertility and of foregoing motherhood is a potential 
hardship to be faced by the patients following treatment of breast cancer. Within the past 10 
years there has been an increasing trend of counseling before treatment (early referral) of 
breast cancer patients regarding fertility preservation. Factors favoring early referrals are 
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older age, early-stage cancer, family history of breast cancer, and academic center 
involvement. [4].  Although the principles of managing breast carcinoma in young women (< 
or = 40 years) are the same as that for older women, breast-conserving surgery is obviously 
desirable in young women. However, these patients have biologically more agressive disease 
with an increase in the risk of local recurrence associated with conservative surgery compared 
with patients older than 60 years. Therefore, younger patients with early breast cancer treated 
with breast-conserving surgery should in particular be followed up at regular intervals so that 
any sign of local failure can be diagnosed early [5].   
Current choice for premenopausal women is an adjuvant therapy, which includes 
cytotoxic chemotherapy, ovarian ablation (by surgery, irradiation or chemical ovarian 
supression), anti-oestrogen therapy or any combination of these. Although the use of adjuvant 
therapies with cytotoxic drugs can significantly reduce the mortality in the majority of young 
women with breast cancer, it raises issues of the long-term toxicity, such as induction of an 
early menopause and fertility impairment. Unfortunately, adjuvant chemotherapy regimens 
commonly used in the treatment of breast cancer may cause premature ovarian failure due to 
their cytotoxic effects on the germ cells in the ovary [5-8]. Therefore, preservation of fertility 
in breast cancer survivors at reproductive age has become an important issue regarding 
quality of life. Fertility preservation is a recently emerged field of reproductive medicine that 
may help protect the reproductive capability of the cancer survivors and allow them to have 
children in the future [9]. This paper reviews the literature regarding the influence of breast 
carcinoma treatment on subsequent fertility, as well as current options available for fertility 
preservation. 
 
2. Surgery and radiotherapy 
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The two principle considerations when deciding between breast-conserving surgery 
versus mastectomy are the cosmetic results and the risk of local recurrence. Although  breast-
conserving  surgery is  regarded desirable in young women, Arrigada et al. [5] have found that 
patients aged less than 40 years at the time of surgery had a 5-fold greater risk of local 
recurrence compared with older patients, but the effect of young age on the risk of local 
recurrence was not seen with mastectomy. Similarly, in the analysis of two large trials of 
mastectomy versus conservative surgery and radiotherapy, Voogd et al. [10] found that 
patients aged less than 35 years had a 9 times higher risk of local recurrence after 
conservative surgery than patients older than 60 years. The most important risk factors for 
local recurrence after breast conserving surgery are younger age (< 35 years), infiltrating 
tumour with an extensive intraductal component, vascular invasion and microscopic 
involvement of excision margins [5,10]. Therefore, Consensus panels of the National 
Institutes of Health  and St. Galen conference have recommended adjuvant therapy for all 
patients aged under 35 years, based on the evidence that they have poor prognosis [11].   
The effect of radiotherapy analysed in a study by Malamos et al. [6]. showed no 
consequence of radiotherapy on the rate and clinical outcome of pregnancy, and at a mean 
follow-up of 18 months no anatomical defects were observed in the offspring. In one of the 
largest studies by Dow et al. [12], of 1624 patients providing information about the influence 
of radiotherapy on later fertility, there were 23 women who had subsequent pregnancies after 
the mean time of 30 months (range 6-84 months). 22 of 23 women deliveried normal full-term 
babies, and the remaining patient a low birth-weight infant, with no adverse clinical outcome 
on pregnancy subsequent to treatment. They reported only diminished lactation from the 
irradiated breast in those women who had undergone radiotherapy following breast-
conserving surgery, which had been presumbly due to atrophy of the breast lobules. Similar 
problem with lactation was noticed in a series of 13 patients by Higgins et al. [13] who 
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reported that 1 patient successfully breast fed following surgery and radiotherapy and 3 
further patients lactated from the treated breast, but were unable to breast feed.      
  
3. Chemotherapy 
With improved education and increased screening, it is likely that more women will be 
diagnosed with early-stage breast cancer at younger ages than ever before. Most national 
guidelines of early-stage invasive breast cancer with negative estrogen receptor recommend 
treatment with adjuvant cytotoxic therapy, and hormone therapy with estrogen positive 
receptor tumours. The exception to these guidelines refers to cases in which the tumours are 
small.Thus, the majority of young women diagnosed at early-stage breast cancer will undergo 
adjuvant chemotherapy. Long-term survival is likely when the breast cancer is diagnosed at 
an early stage, especially after adjuvant cytotoxic therapy [7].  
However, another important aspect of therapy decisions in the young premenopausal 
women undergoing chemotherapy is the preservation of fertility. Although  many of these 
women benefit from chemotherapy, they are afraid to risk the opportunity of bearing children, 
because of ovarian damage and failure, which is an important and unfortunately common 
long-term side effect of curative chemotherapy [14].  Indeed, after such treatments, the 
incidence of amenorrhea  has been reported  to vary from 40% to 68%. Also, the patients who 
recover menses after chemotherapy face the likelyhood of a premature menopause as a result 
of depleted follicular store. These facts represent a serious problem for these cured patients, 
because many of them are relatively young and have expectations of a normal reproductive 
life. The incidence of ovarian failure varies with factors such as the type, duration, total 
cummulative dose of a drug, age of the patient, and possibly on factors yet to be determined 
[15]. The proportion of women developing ovarian failure rises dramatically after the age of 
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40 years, and is irreversible in most cases. The higher grade of ovarian failure in older women 
might be explained by the lower number of remaining follicles [16].   
The exact mechanism of chemotherapy induced ovarian failure is poorly understood. 
An in vitro model has demonstrated that in the human ovary chemotherapy acts primarly on 
primordial follicles, through the induction of apoptotic changes in pregranulosa cells, which 
lead to irreversible loss of follicles and oocytes, along with the evidence of fibrosis [17].  The 
category of the drugs most likely to induce ovarian failure is that of alkylating agents, such as 
cyclophosphamide and melphalan, whereas antimetabolites have a lesser effect. Combination 
chemotherapy is used more often than single agents, and it is therefore difficult to evaluate the 
contribution of each individual drug. The largest body of data on ovarian failure in breast 
carcinoma patients is derived from the experience with cyclophosphamide, methotrexate, and 
5-fluouracil regimen [16].     
In a retrospective review by Sutton et al. [18], of 227 consecutive breast cancer 
patients who were 35 years of age and younger, there were 33 pregnancies in 25 women after 
chemotherapy (of which 10 pregnancies were terminated, 2 patients had spontaneous 
abortions, and 19 patients gave birth to full-term offspring without fetal malformation). Two 
patients were still pregnant at the time of this report. The median interval between the 
completion of treatment and pregnancy was 12 months, and several patients became pregnant 
a few months after treatment. Of the 25 patients who became pregnant, recurrent disease 
subsequently developed in 7, and 3 died. It was concluded that in a sizeable fraction of 
patients aged 35 or younger  treated with adjuvant chemotherapy, ovarian function remained 
intact, and subsequent pregnancy did not affect disease-free interval or survival of the 
patients. The offspring of patients who became pregnant soon after completion of 
chemotherapy showed no adverse effects from the treatment. With regard on teratogenicity of 
adjuvant systemic therapy, Doll et al. [19] have shown that if chemotherapy is administred 
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during pregnancy, there is 16% incidence of fetal malformations in the first trimester, but 
without an increase in the incidence of teratogenesis if  treatment is commenced in the second 
or third trimester. The incidence was lowered to 6% if folate antagonists were used in 
combination with chemotherapy. It has been shown that adjuvant or neoadjuvant 
chemotherapy of breast cancer patients  with antracycline (FAC protocol) can be given 
relatively safely in second and third trimestre of pregnancy  [20, 21]. There are limited data 
on the use of taxanes, or trastusumab in pregnacy, so if indicated, they should be 
administrated in postpartal period, as well as radiation or endocrine therapy [22]  In a study 
by Mulvihill et al. [23], it was found that the children born to women who have conceived 
after cytotoxic therapy, did not appear to be at higher risk for congenital anomalies. However, 
the study reported a 40% rate of abnormal pregnancies, mainly of premature birth and low 
birth weight, both of which were attributed to dysfunction of the uterine hormonal gestational 
milieu. In a study by Blakely et al. [24] the high rate of miscarriage (29%) has been explained 
by the older age of the women, and changes to ovarian function that can occur after 
chemotherapy. Unfortunately, the delayed effects on offspring remain to be determined on 
those who conceive either whilst the mother is undergoing chemotherapy or subsequently. 
Because the risks of recurrence are more frequent during the period of several years following 
chemotherapy Valle et al. [25] recommended the use of barrier contraceptives for a longer 
period. 
 
 
4. Endocrine therapy 
Adjuvant chemotherapy is frequently incorporated as the only useful adjuvant 
treatment into the management of premenopausal women with estrogen receptor negative  
breast cancer. As noted previosuly,  issues of long-term toxicity from chemotherapy for breast 
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cancer, frequently including the induction of premature ovarian failure, appear to be of 
increasing importance for the survivors who  become infertile due to ageing and diminished 
ovarian reserve.  Therefore, avoidance of chemotherapy-related ovarian toxicity may provide 
best prospects for fertility after treatment [9, 16]. For young women with receptor-positive 
breast cancer,  endocrine therapy including ovarian suppression-ablation with gonatrophin 
releasing hormone (GnRH) analogues and tamoxifen, was considered at least a legitimate 
alternative or complement to conventional to chemotherapy [11]. Because several clinical 
trials have found a definitive benefit for combined medical suppression and chemotherapy, it 
has been suggested that the subgroup of premenopausal patients with receptor-positive 
tumours who do not become amenorrheic with chemotherapy, may benefit from the adition of 
reversible ovarian suppression [26, 27]. Ovarian medical suppression combined with 
tamoxifen is currently accepted as an adjuvant endocrine treatment for premenopausal 
receptor-positive breast cancer. This treatment represents a reasonable alternative for women 
with good risk early-stage breast cancer (receptor-positive, lymph node-negative disease), 
particulary those wishing to preserve fertility [8]. It is strongly suggested that the associaton 
of GnRH agonist and tamoxifen offers excellent protection against the endometrial side 
effects induced by tamoxifen. Moreover, tamoxifen appears to be able to reduce the 
significant bone loss induced by GnRH agonist in young  women [28]. However, in a recent 
study it was found that GnRH analogue cotreatment does not offer a significant protective 
effect on ovarian function in patients treated by cyclophosphamide-based chemotherapy [29]. 
Fertility outcomes after common adjuvant chemotherapy regimens for breast cancer by major 
clinical studies are presented in Table 1 [30-42]. 
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5. Current options for fertility preservation 
In recent decades there has been a progress in the field of breast cancer cytotoxic 
treatment, which has led to increasing numbers of survivors, but often with significant 
reproductive impairment. It is reasonable to assume that the preservation of future fertility is 
likely to be a priority for women desiring pregnancy under the age of 40 years. Therefore, 
there are currently several potential options for women facing premature ovarian failure and 
desiring preservation of fertility, including all available assisted technologies, such as in-vitro 
fertilization and embryo transfer (IVF-ET), in vitro maturation, oocyte and embryo 
cryopreservation, and cryopreservation of ovarian tissue  [16, 43-60]. 
 The first reported case of successfully achieved pregnancy using ovarian stimulation 
with human menopausal gonadotrophins and IVF-ET and delivery of a healthy baby was in 
1992 in a patient who had primary infertility for 6 years after radical mastectomy for the 
invasive breast carcinoma [43]. Unfortunately, because of the fact that breast cancer cell 
proliferation and dissemination can be induced by the higher concentrations of estrogen, 
many oncologists currently consider conventional ovarian stimulation  regimens to be 
contraindicated in these patients [44]. Because increased estrogen levels are thought to be 
potentially risky in breast cancer patients, natural cycle IVF in combination with embryo 
cryopreservation has been used to treat infertility and preserve fertility. In addition, it is 
known that tamoxifen, a drug of choice in breast cancer treatment and prophylaxis worldwide, 
has been used for the treatment of annovulatory patients for many years, but it has never been 
used as an ovarian stimulant in IVF cycles [45].  In order do develop a safe ovarian 
stimulation protocol of IVF and fertility preservation in breast cancer patients, Oktay et al. 
[46] compared in their study tamoxifen stimulation with natural cycles during IVF. In the 
group of 12 women on tamoxifen stimulation, who had IVF with either fresh embryo transfer 
or cryopreservation, there was a higher number of embryos in comparison with 5 patients in 
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natural cycles. Although in the group of patients on tamoxifen stimulation there were 
increased estradiol levels comparing with the patients in natural cycles, yet it was regarded 
that tamoxifen could reduce breast cancer incidence with its suppressive effects in these 
patients. In a later study the same authors [47] tried to develop other safe ovarian stimulation 
methods to perform IVF in breast cancer patients. Of 60 women with breast cancer 29 patients 
underwent ovarian stimulation with either tamoxifen alone or in combination with low doses 
of  follicle stimulation hormone (FSH) or aromatase inhibitor letrozole in combination with 
FSH. It was found that tamoxifen or letrozole in combination with low doses of FSH  
stimulation showed similar superiority regarding on the number of embryos, in comparison 
with tamoxifen alone, although the letrozole protocol may be prefered because it results in a 
lower peak of estradiol. In a recent study, it was suggested that in the short term, aromatase 
inhibitors and gonadotrophins are safe and effective agents for ovarian stimulation in fertility 
preservation cycles, supporting the use of aromatase inhibitors for ovarian hyperstimulation in 
women with breast cancer before initiating adjuvant chemotherapy [48].  
Although previous studies [18,19]
 
have not shown any increase of congenital 
malformations in pregnancies occurring long after administration of chemotherapy, the safety 
of using IVF and embryo cryopreservation in breast cancer patients who have recently 
undergone chemotherapy is questionnable. Therefore, further research is needed to define a 
“safety period” between cessation of treatment and oocyte retrieval for IVF. Until definitive 
data are achieved, it would be useful to monitor the pregnancy outcome of all cancer patients 
who undergo oocyte retrieval and IVF, and possibly screen fetuses and babies cytogenetically 
for analyses. However, since recently embryo cryopreservation seems to be the most 
established fertility preservation strategy, providing 25 to 35% chance of pregnancy. In 
addition, oocyte freezing can be considered as an alternative in patients that are single and in 
those who do not wish a sperm donor. Embryo cryopreservation as well as oocyte 
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cryopreservation are considered standard practice and are widely available. Currently, 
embryo/oocyte cryopreservation obtained after controlled ovarian stimulation appears to 
provide the best fertility preservation option. [49]. Ovarian tissue freezing could also be an 
option in breast cancer patients who do not wish or have time for an IVF cycle, which 
requires 10 to 14 days of ovarian stimulation. In a study by Donnez et al. [50], there has been 
reported a livebirth after orthotopic autotransplantation of cryopreserved ovarian tissue. 
Recently Donnez et al. [51] concluded that transplantation of cryopreserved ovarian tissue 
should no longer be considered an experimental procedure, despite the fact that there have 
been „only“ 24 babies born among the 60 patients with reimplantation performed by three 
teams in the last decade. Currently, embryo and mature oocyte cryopreservation following 
IVF are the only techniques endorsed by the American Society of Reproductive Medicine, 
and other methods are still considered to be investigational [52].  The outcome of the various 
fertility preserving options used in cancer patients is presented in Table 2 [51, 53, 54]. In 
clinical situations for which chemotherapy needs to be started for young patients facing 
premature ovarian failure, ovarian tissue preservation seems to be a promissing option of 
restoring fertility, in conjuction with other options, like immature oocyte retrieval, in-vitro 
maturation of oocytes, oocyte vitrification, or embryo cryopreservation. It seems that in-vitro 
maturation is a useful strategy because it improves oocyte or cryopreservation outcome in 
breast cancer patients undergoing ovarian stimulation for fertility preservation [55]. Fertility 
preservation for breast-cancer patients using in-vitro maturation followed by oocyte or 
embryo vitrification calculated through pregnancy rates per vitrified oocyte and embryo were 
3.8% and 8.1%, respectively [56]. The development of fertility preservation has recently 
opened new perspectives in the field of in-vitro maturation. The combination of ovarian tissue 
cryopreservation with immature oocyte collection from the tissue followed by oocyte 
vitrification via in-vitro maturation represents another promising approach of new trends in 
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fertility preservation in young women with cancer [57]. However, the risk of cryopreserving 
and transferring malignant cells with reimplantation remains, so screening methods with 
immunohistochemical markers should be developed to detect minimal residual disease. 
Among the different  pathologies investigated, the highest risk of reimplanting malignant cells 
was found with leukemia. Therefore, for ovarian tissue from patients with hematologic 
malignancies, it is of paramount imporance to identify minimal residual disease before 
ovarian tissue transplantation [58]. Although the last decade has brought many options for 
women with breast cancer considering fertility preservation, but numerous challenges remain. 
The presence of BRCA mutations further contributes to these challenges and studies specific 
for women with BRCA mutations are lacking. Women with BRCA mutations may elect to 
use preimplantation genetic diagnosis during in vitro fertilization to avoid transmitting the 
mutation [59]. Since there are some indications that BRCA 1 mutations could be related to 
diminished ovarian reserve, familiar breast cancer should be the subject of further research. 
[60]. In the future, it is necessary to improve freezing techniques and enhance the vascular 
bed before implantation to increase pregnancy rates [50]. In addition, more studies are needed 
to determine the real role of different preservation options in breast cancer patients. Moreover, 
the long term influence of different breast carcinoma treatment modalities (such as longer 
hormonal therapy, immunotherapy or radio therapy) remains to be determined.  
 
 
6. Conclusion 
It is known that in the past many women with breast cancer thought that the 
information about later fertility they have received was either insufficient or unavailable. This 
information might not be actual at the time of diagnosis, but it becomes very important after 
diagnosis of breast cancer. Currently, several fertility-sparing options with the use of assisted 
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reproductive technology have been developed, and they are available before, during, and after 
treatment of breast cancer. Therefore, many women consider that the information about 
fertility should be given prior or after breast cancer treatment. Because fertility after breast 
cancer is a major concern for young women desiring pregnancy, the patient′s  future chance of 
pregnancy should be maximized by organizing an appropriate assisted reproduction center                
with a multidisciplinary team as soon as the diagnosis is made, rather than after the treatment, 
to enable patients to discuss their options for fertility preservation.                            
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Table  1. Rates of amenorrhea categorized by patient age group after common adjuvant 
chemotherapy regimens for breast cancer  
Regimen Study Number of 
Patients 
Number of 
cycles 
Age of 
patients 
(years) 
Amenorrhea 
(%) 
CMF Goldhirsch et 
al. [30] 
387 6-7 ≥40 81 (vs. 26% 
without 
chemo) 
<40 33 (vs. 6% 
without 
chemo) 
  Pagani et al. 
[31] 
1,196 3-9 ≥40 74 
<40 18 
  Castiglione et 
al. [32] 
360 6 ≥40 90 
<40 40 
  Bianco et al. 
[33]  
221 6-9 +/- 
tamoxifen 
≥40 86 
<40 33 
  Jonat et al. 
[34] 
823 6 ≥40 90 
<40 26 
AC Tramyl et al.  
[35]  
77 4 ≥40 81 
<40 44 
FEC Roche et al. 
[36] 
169 6 ≥40 73 
<40 38 
  Lupors et al. 
[37] 
249 Up to 6 ≥40 88 
<40 32 
Epirubicin 
based 
Borde et al. 
[38]. 
1,103 3-6 <40 34 
            
Anthracycline 
and taxane 
based 
Ganz et al. 
[39] 
793 4c AC -> 4c 
docetaxel 
Premenopausal 70 
806 8c TAC 58 
  Tramyl et al. . 
[35].  
118 4c AC → 3m 
taxane 
≥40 84 
<40 61 
  Fornier et al. 
[40] 
166 AC -> taxane 
(variable 
cycles) 
≤40 13 
82 + endocrine 17 
  Samuelkutty et 
al. [41] 
140 4c EC → 4c 
docetaxel 
>40 86 
<40 46 
  Martin et al. 
[42] 
421 6c TAC  Premenopausal 62 
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Note: CMF –cyclophosphamide, methotrexate, and 5-fluorouracil; AC –doxorubicin and 
cyclophosphamide; TAC – docetaxel, doxorubicine and cyclophosphamide; EC-epyrubicin, 
cyclophosphamide; FEC-5-fluorouracil, epirubicin, cyclophosphamide; c-cycles 
 
 
Table 2. The outcome of the various fertility preserving options used in cancer patients 
 
___________________________________________________________________________ 
 
Fertility preserving options          References                     Patients                Births
            
___________________________________________________________________________ 
 
Oocyte cryopreservation      Garcia-Velasco et al. [53]              355                       6                           
 
Embryo cryopreservation            Barcroft et al. [54]                42                        3   
 
Transplantation of cryo-              Donnez et al. [51]                            60                     24 
preserved ovarian tissue               
 
___________________________________________________________________________ 
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